Telix Pharmaceuticals Limited (TLX)

NASDAQ: TLX · Real-Time Price · USD
9.64
+0.35 (3.77%)
Sep 10, 2025, 11:03 AM - Market open
3.77%
Market Cap3.21B
Revenue (ttm)664.23M
Net Income (ttm)10.84M
Shares Out 338.40M
EPS (ttm)0.04
PE Ratio226.31
Forward PE29.85
Dividendn/a
Ex-Dividend Daten/a
Volume139,488
Open9.54
Previous Close9.29
Day's Range9.49 - 9.72
52-Week Range8.93 - 30.36
Beta2.38
AnalystsStrong Buy
Price Target21.33 (+121.27%)
Earnings Daten/a

About TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 234
Stock Exchange NASDAQ
Ticker Symbol TLX
Full Company Profile

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was $484.69 million, an increase of 41.49% compared to the previous year's $342.57 million. Earnings were $30.89 million, an increase of 769.68%.

Financial numbers in USD Financial Statements

Analyst Summary

According to 3 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $21.33, which is an increase of 121.27% from the latest price.

Price Target
$21.33
(121.27% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Telix Pharmaceuticals Limited (TLX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Telix Pharmaceuticals Limited (NASDAQ:TLX) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 12:00 PM EDT Company Participants Christian Behrenbruch - Co-Founder, MD, Group C...

15 hours ago - Seeking Alpha

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 cli...

16 hours ago - GlobeNewsWire

Telix Pharmaceuticals Limited (TLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Telix Pharmaceuticals Limited (NASDAQ:TLX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:50 PM EDT Company Participants Christian Behrenbruch - Co-Founder, MD, Group CEO...

1 day ago - Seeking Alpha

Telix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens Berman

SAN FRANCISCO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- On August 28, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares fall about 16% after the...

11 days ago - GlobeNewsWire

Telix Pharmaceuticals: Roadblocks Piling Up, But They're Not Insurmountable

Despite recent FDA rejections and a ~50% share price drop, I remain bullish on TLX, viewing setbacks as surmountable. Strong revenue performance and cash flow stability provide TLX with ample runway t...

11 days ago - Seeking Alpha

Telix Gets Second FDA Rejection For Kidney Cancer Drug

On Thursday, Telix Pharmaceuticals Limited TLX received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zi...

12 days ago - Benzinga

US FDA seeks more information on Telix Pharma's diagnostic drug for kidney cancer

The U.S. Food and Drug Administration has requested additional data from Telix Pharmaceuticals on its application for a diagnostic drug to detect a form of kidney cancer, the Australian cancer diagnos...

13 days ago - Reuters

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

SAN FRANCISCO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after t...

14 days ago - GlobeNewsWire

Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference

MELBOURNE, Australia and INDIANAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will present at the Morgan Stanley 23rd Annual Global Healthcare...

15 days ago - GlobeNewsWire

TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm

LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Telix Pharmaceutical...

16 days ago - PRNewsWire

Telix Pharmaceuticals Limited (TLX) Q2 2025 Earnings Call Transcript

Telix Pharmaceuticals Limited (NASDAQ:TLX) Q2 2025 Earnings Conference Call August 20, 2025 7:30 PM ET Company Participants Christian P. Behrenbruch - Co-Founder, MD, Group CEO & Executive Director D...

18 days ago - Seeking Alpha

Telix Pharmaceuticals Limited Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – TLX

LOS ANGELES--(BUSINESS WIRE)--The DJS Law Group announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violation...

19 days ago - Business Wire

Telix Pharmaceuticals Limited (TLPPF) H1 2025 Earnings Call Transcript

Telix Pharmaceuticals Limited (OTCPK:TLPPF) H1 2025 Earnings Conference Call August 20, 2025 7:30 PM ET Company Participants Christian P. Behrenbruch - Co-Founder, MD, Group CEO & Executive Director D...

20 days ago - Seeking Alpha

Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth

MELBOURNE, Australia and INDIANAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30...

20 days ago - GlobeNewsWire

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena – Hagens Berman

SAN FRANCISCO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after t...

4 weeks ago - GlobeNewsWire

Telix H1 2025 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the...

6 weeks ago - GlobeNewsWire

Telix Pharmaceuticals: Assessing The Market's Pullback On SEC Inquiry

TLX boasts a diverse pipeline and strong sales growth, especially with Illuccix and Gozellix, supporting my continued confidence in their theranostics approach. Financials remain robust, with year-ove...

6 weeks ago - Seeking Alpha

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational perfo...

7 weeks ago - GlobeNewsWire

Gozellix Receives Permanent HCPCS Code

MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its next-generation PSMA1 PET2 imaging agen...

2 months ago - GlobeNewsWire

Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Foo...

2 months ago - GlobeNewsWire

Telix Precision Medicine Announces AlFluor Radiochemistry Platform

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it has launched a novel PET1 radi...

2 months ago - GlobeNewsWire

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and t...

2 months ago - GlobeNewsWire

Telix Investor Day in New York City on June 11, 2025: Presenting KOLs

MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) provides further details on the agenda for the Co...

3 months ago - GlobeNewsWire

Telix Pharmeceuticals: Imaging Biomarkers Paving The Way For Theranostics

Telix Pharmaceuticals excels in radiopharmaceuticals, with strong revenue growth driven by imaging products like Illuccix and promising therapeutic programs in development. TLX's key imaging projects ...

4 months ago - Seeking Alpha

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

MELBOURNE, Australia and INDIANAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein...

4 months ago - GlobeNewsWire